bleselumab
mAbexperimental
Bleselumab is a human monoclonal antibody designed for the prevention of organ transplant rejection. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT01565681)
Timeline
Indications
Mechanism of action
Tumor necrosis factor receptor superfamily member 5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBleselumab ↗
- ChEMBLCHEMBL3990028 ↗
Also known as
- asp1240
- bleselumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02921789 | Phase 2 | Dec 22, 2016 | Astellas, Kyowa Hakko Kirin |
| NCT01565681 | Phase 1 | Jan 1, 2009 | Astellas, Kyowa Hakko Kirin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 2 | 2009 |
| Kyowa Hakko Kirin | For profit | 2 | 0 | 2 | 2009 |
2 organizations
Page 1 / 1